Are Anti-TNF-α Agents Safe for Treating Psoriasis in Hepatitis C Virus Patients with Advanced Liver Disease? Case Reports and Review of the Literature

Dermatology

Volumn 232, Issue 1, 2016, Pages 102-106

  Di Nuzzo, Sergio ^a   Boccaletti, Valeria ^a   Fantini, Carolina ^a   Cortelazzi, Chiara ^a   Missale, Gabriele ^b   Fabrizi, Giuseppe ^a   Lotti, Torello ^c   Hercogová, Jana ^d   Pagliarello, Calogero ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c UNIVERSITY OF ROME G MARCONI   (Italy)

^d UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

Author keywords

Etanercept; Hepatitis C virus infection; Hepatocellular carcinoma; Psoriasis

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN GLUCURONIDE; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; ETANERCEPT; ETRETIN; GAMMA GLUTAMYLTRANSFERASE; LEFLUNOMIDE; METHOTREXATE; PEGINTERFERON ALPHA2A; RIBAVIRIN; SALICYLIC ACID; VITAMIN D DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIRUBIN BLOOD LEVEL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG CONTRAINDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MONOTHERAPY; MORNING STIFFNESS; NEPHROLITHIASIS; PHYSIOTHERAPY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PSORIASIS; RECURRENT DISEASE; REVIEW; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CHRONIC HEPATITIS C; COMPLICATION; LIVER NEOPLASMS; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; ETANERCEPT; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84958107426     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000439587     Document Type: Review

References (24)

1. Frankel AJ, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, Gottlieb AB: Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 61: 1044-1055.
2. Costa L, Caso F, Atteno M, et al: Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: A retrospective observational multicenter study on 15 patients. Clin Rheumatol 2014; 33: 273-276.
3. Caso F, Cantarini L, Morisco F, et al: Current evidence in the field of the management with TNF-A inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opin Biol Ther 2015; 15: 641-650.
4. Lehnen M, Franckson T, Knab J, Hoeft D, Grabbe S, Dissemond J: Successful infliximab therapy of psoriasis vulgaris and psoriatic arthritis in a patient with cirrhosis. Br J Dermatol 2005; 153: 212-214.
5. Lehnen M, Franckson T, Korber A, Grabbe S, Dissemond J: Etanercept therapy of psoriatic arthritis in a patient with liver cirrhosis. Acta Derm Venereol 2005; 85: 351-352.
6. Piel S, Dissemond J: Adalimumab therapy of psoriasis and psoriatic arthritis in a patient with cirrhosis of the liver. J Am Acad Dermatol 2008; 59:S117-S118.
7. Spadaro A, Scrivo R, Riccieri V, Valesini G: Effect of tumour necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis. Joint Bone Spine 2008; 75: 87-89.
8. Ogata A, Terabe F, Nakanishi K, et al: Etanercept improved primary biliary cirrhosis associated with rheumatoid arthritis. Joint Bone Spine 2009; 76: 105-107.
9. Kubo S, Iwata S, Saito K, Tanaka Y: Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis. Joint Bone Spine 2011; 78: 535-536.
10. Dhere T: Use of biologics in inflammatory bowel disease patients with cirrhosis. Inflamm Bowel Dis 2011; 17:E15-E16.
11. Chen SC, Cummings OW, Hartley MP, Filomena CA, Cho WK: Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab. Dig Dis Sci 2006; 51: 952-955.
12. Kumar A, Le DT: Hepatocellular carcinoma regression after cessation of immunosuppressive therapy. J Clin Oncol 2014, Epub ahead of print.
13. Murakami A, Tanaka Y, Ueda M, Nagano Y, Kunisaki R, Morimoto M, Enaka M, Tanabe M, Kawachi K, Sasaki T, Nozawa A: Hepatocellular carcinoma occurring in a young Crohn's disease patient. Pathol Int 2009; 59: 492-496.
14. Ishida M, Naka S, Shiomi H, Tsujikawa T, Andoh A, Nakahara T, Saito Y, Kurumi Y, Takikita-Suzuki M, Kojima F, Hotta M, Tani T, Fujiyama Y, Okabe H: Hepatocellular carcinoma occurring in a Crohn's disease patient. World J Gastroenterol 2010; 16: 3215-3218.
15. Collazo MH, González JR, Torres EA: Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant. P R Health Sci J 2008; 27: 346-347.
16. Navarro R, Vilarrasa E, Herranz P, et al: Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: A retrospective, multicentre study in a clinical setting. Br J Dermatol 2013; 168: 609-616.
17. Vento S, Cainelli F: Does hepatitis C virus cause severe liver disease only in people who drink alcohol? Lancet Infect Dis 2002; 2: 303-309.
18. Chuang E, Del Vecchio A, Smolinski S, Song XY, Sarisky RT: Biomedicines to reduce inflammation but not viral load in chronic HCV-what's the sense? Trends Biotechnol 2004; 22: 517-523.
19. Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, Lee VK, Lee KH, Abastado JP, Toh HC, Nardin A: Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 2010; 52: 370-379.
20. El-Serag HB: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 87-107.
21. Donato F, Tagger A, Chiesa R, et al: Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: A case-control study in Italy. Brescia HCC Study. Hepatology 1997; 26: 579-584.
22. Lok AS, Seeff LB, Morgan TR, et al: Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-148.
23. Atteno M, Costa L, Matarese A, et al: The use of TNF-A blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol 2014; 33: 543-547.
24. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.